103 related articles for article (PubMed ID: 17088988)
1. The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
Suggitt M; Cooper PA; Shnyder SD; Bibby MC
Int J Oncol; 2006 Dec; 29(6):1493-9. PubMed ID: 17088988
[TBL] [Abstract][Full Text] [Related]
2. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
3. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.
Suggitt M; Swaine DJ; Pettit GR; Bibby MC
Clin Cancer Res; 2004 Oct; 10(19):6677-85. PubMed ID: 15475458
[TBL] [Abstract][Full Text] [Related]
5. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
6. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
Shnyder SD; Hasan J; Cooper PA; Pilarinou E; Jubb E; Jayson GC; Bibby MC
Anticancer Res; 2005; 25(3B):1889-94. PubMed ID: 16158922
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.
Burger AM; Jenkins TC; Double JA; Bibby MC
Br J Cancer; 1999 Sep; 81(2):367-75. PubMed ID: 10496367
[TBL] [Abstract][Full Text] [Related]
8. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
[TBL] [Abstract][Full Text] [Related]
9. The hollow fibre model in cancer drug screening: the NCI experience.
Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA
Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous transformation of human granulosa cell tumours into an aggressive phenotype: a metastasis model cell line.
Imai M; Muraki M; Takamatsu K; Saito H; Seiki M; Takahashi Y
BMC Cancer; 2008 Nov; 8():319. PubMed ID: 18980698
[TBL] [Abstract][Full Text] [Related]
11. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
12. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
15. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
16. [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Zhao GZ; Tan WL; Zheng SB; Wu YD; Xie Y; Zhu WH
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1623-5, 1628. PubMed ID: 17121717
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
18. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.
Guichard SM; Macpherson JS; Thurston DE; Jodrell DI
Eur J Cancer; 2005 Aug; 41(12):1811-8. PubMed ID: 16046116
[TBL] [Abstract][Full Text] [Related]
19. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
